As the current flu season highlights the need for a universal flu vaccine and more potent flu shots produced in cells instead of eggs, Sanofi Pasteur has signed a deal potentially worth $155 million to license cell culture technology from South Korea’s SK Chemicals.Original Article
As raging flu epidemic spreads, Sanofi Pasteur targets more effective cell-based universal vaccine
